These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 30240132)
1. Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function. Tortorici MA; Duffy D; Evans R; Feaster J; Gille A; Mant TGK; Wright SD; D'Andrea D Clin Pharmacol Drug Dev; 2019 Jul; 8(5):628-636. PubMed ID: 30240132 [TBL] [Abstract][Full Text] [Related]
2. Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity. Gille A; Duffy D; Tortorici MA; Wright SD; Deckelbaum LI; D'Andrea DM J Clin Pharmacol; 2019 Mar; 59(3):427-436. PubMed ID: 30452776 [TBL] [Abstract][Full Text] [Related]
3. The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. Gibson CM; Kerneis M; Yee MK; Daaboul Y; Korjian S; Mehr AP; Tricoci P; Alexander JH; Kastelein JJP; Mehran R; Bode C; Lewis BS; Mehta R; Duffy D; Feaster J; Halabi M; Angiolillo DJ; Duerschmied D; Ophuis TO; Merkely B Am Heart J; 2019 Feb; 208():81-90. PubMed ID: 30580130 [TBL] [Abstract][Full Text] [Related]
4. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Michael Gibson C; Korjian S; Tricoci P; Daaboul Y; Yee M; Jain P; Alexander JH; Steg PG; Lincoff AM; Kastelein JJ; Mehran R; D'Andrea DM; Deckelbaum LI; Merkely B; Zarebinski M; Ophuis TO; Harrington RA Circulation; 2016 Dec; 134(24):1918-1930. PubMed ID: 27881559 [TBL] [Abstract][Full Text] [Related]
5. Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. Tricoci P; D'Andrea DM; Gurbel PA; Yao Z; Cuchel M; Winston B; Schott R; Weiss R; Blazing MA; Cannon L; Bailey A; Angiolillo DJ; Gille A; Shear CL; Wright SD; Alexander JH J Am Heart Assoc; 2015 Aug; 4(8):e002171. PubMed ID: 26307570 [TBL] [Abstract][Full Text] [Related]
6. CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial. Gibson CM; Kazmi SHA; Korjian S; Chi G; Phillips AT; Montazerin SM; Duffy D; Zheng B; Heise M; Liss C; Deckelbaum LI; Wright SD; Gille A J Cardiovasc Pharmacol Ther; 2022; 27():10742484221121507. PubMed ID: 36282079 [TBL] [Abstract][Full Text] [Related]
7. A multiple ascending dose study of CSL112, an infused formulation of ApoA-I. Easton R; Gille A; D'Andrea D; Davis R; Wright SD; Shear C J Clin Pharmacol; 2014 Mar; 54(3):301-10. PubMed ID: 24122814 [TBL] [Abstract][Full Text] [Related]
8. Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. Gibson CM; Korjian S; Tricoci P; Daaboul Y; Alexander JH; Steg PG; Lincoff AM; Kastelein JJ; Mehran R; D'Andrea D; Merkely B; Zarebinski M; Ophius TO; Harrington RA Am Heart J; 2016 Oct; 180():22-8. PubMed ID: 27659879 [TBL] [Abstract][Full Text] [Related]
9. Effect of CSL112 (apolipoprotein A-I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross-study comparison. Zheng B; Goto S; Clementi R; Feaster J; Duffy D; Dalitz P; Airey J; Korjian S; Tortorici MA; Roberts J; Gibson CM Clin Transl Sci; 2022 Oct; 15(10):2331-2341. PubMed ID: 35933730 [TBL] [Abstract][Full Text] [Related]
15. CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction. Capodanno D; Mehran R; Gibson CM; Angiolillo DJ Expert Opin Investig Drugs; 2018 Dec; 27(12):997-1005. PubMed ID: 30376729 [TBL] [Abstract][Full Text] [Related]
16. Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. Gibson CM; Kastelein JJP; Phillips AT; Aylward PE; Yee MK; Tendera M; Nicholls SJ; Pocock S; Goodman SG; Alexander JH; Lincoff AM; Bode C; Duffy D; Heise M; Berman G; Mears SJ; Tricoci P; Deckelbaum LI; Steg PG; Ridker P; Mehran R Am Heart J; 2021 Jan; 231():121-127. PubMed ID: 33065120 [TBL] [Abstract][Full Text] [Related]
17. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Diditchenko S; Gille A; Pragst I; Stadler D; Waelchli M; Hamilton R; Leis A; Wright SD Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2202-11. PubMed ID: 23868939 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. Gurbel PA; Tantry US; D'Andrea D; Chung T; Alexander JH; Bliden KP; Wright SD; Tricoci P J Thromb Thrombolysis; 2018 May; 45(4):469-476. PubMed ID: 29582212 [TBL] [Abstract][Full Text] [Related]
19. Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study. Kim S; Lee J; Shin D; Lim KS; Kim YS; Jang IJ; Yu KS Drug Des Devel Ther; 2014; 8():1723-31. PubMed ID: 25336916 [TBL] [Abstract][Full Text] [Related]
20. Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction. Korjian S; Kazmi SHA; Chi G; Kalayci A; Lee JJ; Talib U; Wright SD; Duffy D; Kingwell BA; Mehran R; Ridker PM; Gibson CM Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):387-398. PubMed ID: 36787889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]